Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
The pivotal Phase 2 ALPHA3 trial for Cema-Cel in LBCL has nearly 50 activated sites across the U.S., with over 250 patients consented for MRD screening. However, the lymphodepletion selection and futility analysis has been delayed to 1H 2026 due to site-related factors.
The company implemented cost-realignment measures to extend cash runway into 2H 2027, focusing on advancing Cema-Cel/ALPHA3 and ALLO-329/RESOLUTION trials. The RESOLUTION trial for autoimmune diseases is set to begin mid-2025, while updated Phase 1 ALLO-316 trial results in renal cell carcinoma will be presented at ASCO 2025.
2025 guidance projects a decrease in cash of approximately $150 million with GAAP operating expenses around $230 million.
Lo studio pivotale di Fase 2 ALPHA3 per Cema-Cel nel LBCL conta quasi 50 siti attivati negli Stati Uniti, con oltre 250 pazienti che hanno dato il consenso per lo screening MRD. Tuttavia, la selezione per la linfo-deplezione e l'analisi di inefficacia sono state posticipate al primo semestre 2026 a causa di fattori legati ai siti.
L’azienda ha adottato misure di riallineamento dei costi per estendere la liquidità fino alla seconda metà del 2027, concentrandosi sull’avanzamento degli studi Cema-Cel/ALPHA3 e ALLO-329/RESOLUTION. La sperimentazione RESOLUTION per le malattie autoimmuni inizierà a metà 2025, mentre i risultati aggiornati della Fase 1 dello studio ALLO-316 sul carcinoma a cellule renali saranno presentati all’ASCO 2025.
Le previsioni per il 2025 indicano una riduzione della liquidità di circa 150 milioni di dollari con spese operative GAAP intorno a 230 milioni di dollari.
El ensayo pivotal de Fase 2 ALPHA3 para Cema-Cel en LBCL cuenta con casi 50 sitios activados en Estados Unidos, con más de 250 pacientes que han dado su consentimiento para el cribado de MRD. Sin embargo, la selección para linfodepleción y el análisis de inutilidad se han retrasado hasta la primera mitad de 2026 debido a factores relacionados con los sitios.
La empresa implementó medidas de reajuste de costos para extender la liquidez hasta la segunda mitad de 2027, enfocándose en avanzar los ensayos Cema-Cel/ALPHA3 y ALLO-329/RESOLUTION. El ensayo RESOLUTION para enfermedades autoinmunes comenzará a mediados de 2025, mientras que los resultados actualizados del ensayo de Fase 1 ALLO-316 en carcinoma de células renales se presentarán en ASCO 2025.
La guía para 2025 proyecta una disminución del efectivo de aproximadamente 150 millones de dólares con gastos operativos GAAP alrededor de 230 millones de dólares.
LBCL 대상 Cema-Cel의 중추적 2상 ALPHA3 임상시험은 미국 내 거의 50개 활성 사이트를 보유하고 있으며, 250명 이상의 환자가 MRD 선별 동의를 완료했습니다. 다만, 사이트 관련 요인으로 인해 림프절 고갈 선정 및 무효성 분석은 2026년 상반기로 연기되었습니다.
회사는 비용 재조정 조치를 시행하여 현금 유동성을 2027년 하반기까지 연장하고, Cema-Cel/ALPHA3 및 ALLO-329/RESOLUTION 임상시험 진전에 집중하고 있습니다. 자가면역질환 대상 RESOLUTION 시험은 2025년 중반에 시작될 예정이며, 신세포암 대상 1상 ALLO-316 시험의 최신 결과는 ASCO 2025에서 발표됩니다.
2025년 가이던스는 현금 약 1억 5천만 달러 감소와 GAAP 영업비용 약 2억 3천만 달러를 예상하고 있습니다.
L’essai pivot de phase 2 ALPHA3 pour Cema-Cel dans le LBCL compte près de 50 sites activés aux États-Unis, avec plus de 250 patients ayant consenti au dépistage MRD. Cependant, la sélection pour la lymphodéplétion et l’analyse d’inutilité ont été retardées au premier semestre 2026 en raison de facteurs liés aux sites.
La société a mis en place des mesures de réalignement des coûts afin de prolonger sa trésorerie jusqu’à la seconde moitié de 2027, en se concentrant sur l’avancement des essais Cema-Cel/ALPHA3 et ALLO-329/RESOLUTION. L’essai RESOLUTION pour les maladies auto-immunes devrait débuter à la mi-2025, tandis que les résultats mis à jour de l’essai de phase 1 ALLO-316 dans le carcinome à cellules rénales seront présentés à l’ASCO 2025.
Les prévisions pour 2025 projettent une diminution des liquidités d’environ 150 millions de dollars avec des dépenses opérationnelles GAAP d’environ 230 millions de dollars.
Die entscheidende Phase-2-Studie ALPHA3 für Cema-Cel bei LBCL hat fast 50 aktivierte Standorte in den USA, mit über 250 Patienten, die für das MRD-Screening zugestimmt haben. Die Auswahl für die Lymphodepletion und die Futility-Analyse wurden jedoch aufgrund von standortbezogenen Faktoren auf das erste Halbjahr 2026 verschoben.
Das Unternehmen hat Kostenanpassungsmaßnahmen umgesetzt, um die Liquidität bis zur zweiten Hälfte 2027 zu verlängern, wobei der Fokus auf der Weiterentwicklung der Studien Cema-Cel/ALPHA3 und ALLO-329/RESOLUTION liegt. Die RESOLUTION-Studie für Autoimmunerkrankungen soll Mitte 2025 starten, während aktualisierte Ergebnisse der Phase-1-Studie ALLO-316 bei Nierenzellkarzinom auf der ASCO 2025 präsentiert werden.
Die Prognose für 2025 sieht einen Bargeldrückgang von etwa 150 Millionen US-Dollar bei GAAP-Betriebskosten von rund 230 Millionen US-Dollar vor.
- Extended cash runway into 2H 2027 through cost optimization measures
- Strong site activation with nearly 50 sites for ALPHA3 trial across U.S.
- Over 250 patients consented for MRD screening, with nearly half in last three months
- International expansion of ALPHA3 trial to Canada in Q2 2025
- Healthy cash position of $335.5M as of Q1 2025
- Delayed lymphodepletion selection and futility analysis to 1H 2026 due to site-related factors
- Net loss of $59.7 million in Q1 2025
- Expected decrease in cash of approximately $150 million in 2025
- Reduction in manufacturing operations
Insights
Allogene reports mixed Q1 results with clinical trial delays but secures extended cash runway into 2H 2027 through strategic cost-cutting.
Allogene's Q1 2025 report reveals significant timeline delays for key clinical milestones in their lead programs. The pivotal ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) in first-line large B-cell lymphoma has seen the lymphodepletion selection and futility analysis pushed back by approximately six months to 1H 2026. This delay stems primarily from site-related factors slowing patient screening post-activation. While the company has activated nearly 50 sites across the U.S., the extended timeline suggests challenges in operational execution despite reporting
Similarly, their ALLO-329 program in autoimmune diseases is experiencing timeline shifts, with proof-of-concept data now delayed to 1H 2026 to incorporate both biomarker and clinical data. The RESOLUTION basket trial in rheumatology remains on track for mid-2025 start.
Financially, Allogene reported a quarterly net loss of
The ALLO-316 program in renal cell carcinoma appears to be progressing as expected, with updated Phase 1b data scheduled for presentation at ASCO in June 2025. The company highlights that this is the only allogeneic CAR-T therapy showing potential in solid tumors, which represents a potentially significant differentiation point in their pipeline.
The extended cash runway provides Allogene with crucial financial flexibility to weather clinical development challenges, but investors should carefully monitor the company's ability to execute on revised timelines given the pattern of delays across multiple programs.
- Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL)
- Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from Investigators
- Lymphodepletion Selection and Futility Analysis Shifted to 1H 2026 in Part Due to Site-Related Factors that Impacted Expected Pace of Screening Immediately Following Site Activation
- Over 250 Patients Consented for MRD Screening to Date, with Nearly Half in the Last Three Months and Awaiting Completion of 1L Treatment as Earliest Activated Sites Build Momentum
- International Expansion of ALPHA3 Trial to Begin with Site Activations in Canada in Q2 2025
- Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID)
- RESOLUTION Basket Trial in Rheumatology on Track for Mid-2025 Start
- Proof-of-Concept Data Moved to 1H 2026 to Enable Inclusion of Both Biomarker and Clinical Data
- Phase 1 TRAVERSE Trial with ALLO-316 in Renal Cell Carcinoma (RCC)
- Updated Phase 1 Trial Results Will be Featured in an Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- Presentation to Highlight Meaningful Clinical Responses from the Phase 1B Expansion Cohort and Key Translational Findings, Including Ability for CD70 Dagger® Technology to Drive Robust CAR T Cell Expansion and Persistence
- Ended Q1 2025 with
$335.5 Million in Cash, Cash Equivalents and Investments- Cost Realignment and Strategic Prioritization Will Extend Cash Runway Into 2H 2027
- Spend Focused on Advancing the Cema-Cel/ALPHA3 and ALLO-329/RESOLUTION Clinical Trials to Key Inflection Points
- Targeted Reductions in Manufacturing Operations Provide Key Savings While Preserving Core Capabilities
- Conference Call and Webcast Scheduled for Today at 2:00 PM PT/5:00 PM ET
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended March 31, 2025.
“We are executing on a strategy that is grounded in science, shaped by real-world insights, and supported by a platform purpose-built to scale,” said David Chang, M.D., Ph.D., President, Chief Executive Officer, and Co-Founder of Allogene. “From transforming the role of CAR T in first line LBCL through ALPHA3 to breaking new ground in autoimmune disease with ALLO-329 to showing what’s possible in solid tumors with ALLO-316, we are leading where others have yet to go. The experience we’ve gained from our trials, the commitment from our partners, and the unmatched efficiencies of our allogeneic platform reinforce my confidence that our approach is not only working but also defining the future of cell therapy. We have never been clearer about our path or more certain about the value we can deliver to patients and the field.”
Program Updates
Cema-Cel: Pivotal Phase 2 ALPHA3 1L Consolidation Trial in LBCL
The ALPHA3 trial evaluating cema-cel as 1L consolidation therapy for LBCL remains a cornerstone of Allogene’s clinical strategy. The trial now includes nearly 50 activated sites across the U.S., spanning both community cancer centers and leading academic institutions. The trial uniquely identifies high-risk patients using Foresight CLARITY™ powered by PhasED-Seq™, an Investigational Use Only (IUO) MRD test, and randomizes approximately 240 patients to assess whether early intervention with cema-cel improves event-free survival (EFS) compared to observation, which is the current standard of care.
As the first study of its kind, ALPHA3 has delivered valuable real-world insights. Since launching in mid-2024, Allogene has partnered closely with sites to refine patient identification strategies; educated patients on their relapse risk and opportunity for additional therapy based on MRD status; and navigated expected and unforeseen challenges. Chief among these has been industry-wide factors that have delayed site readiness to initiate screening activities for three months or more after activation. As a result, the milestone for lymphodepletion regimen selection and futility analysis has been shifted by approximately two quarters and is now expected in the first half of 2026.
The momentum behind ALPHA3 however has been tangible and significant, driven by a strong partnership between Allogene and its clinical sites. Several sites have proactively collaborated with the Company to develop and share best practices, fostering a coordinated network. An important measure of success is the identification of patients early in 1L treatment who are interested in the trial and consenting them for MRD testing at completion of therapy. This metric is now being consistently met as earlier introduction to the trial has increased the proportion of screening-eligible patients advancing to MRD testing and, if positive, agreeing to randomization. With the earliest activated sites now screening regularly and newly activated sites implementing best practices immediately, we have now consented over 250 patients for MRD screening, with nearly half of these consents occurring in the last three months. Meanwhile, growing international interest has prompted expansion of the trial footprint outside the U.S., a move expected to accelerate enrollment further and strengthen trial execution.
The Company will intentionally hold off on projecting additional milestones until after the first milestone for lymphodepletion regimen selection and futility analysis. Recognizing the strategic significance of this inflection point and guided by stakeholder feedback, the Company is re-evaluating what data will be appropriate to share at the time of the lymphodepletion announcement.
ALLO-329: CD19/CD70 Dual CAR with Dagger® Technology in AID
ALLO-329 offers a novel approach to treating autoimmune diseases as the first allogeneic CD19/CD70 dual CAR T product specifically designed to target CD19+ B-cells and CD70+ activated T-cells, both of which are key players in autoimmune diseases. The investigational product utilizes CRISPR-based site-specific integration and incorporates the Company’s clinically validated Dagger® technology, which aims to reduce or eliminate the need for lymphodepletion, believed to be a potentially significant obstacle to the broader adoption of CAR T therapies in autoimmune indications.
The Phase 1 RESOLUTION basket trial in rheumatology will begin in mid-2025. The trial will include patients with systemic lupus erythematosus, including lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis. The innovative design of the RESOLUTION trial will include two distinct lymphodepletion arms: one using a dose of cyclophosphamide alone and another that eliminates lymphodepletion entirely. The Company has shifted timing for its first update to this program to 1H 2026 to allow for both biomarker and clinical proof-of-concept data.
ALLO-316: TRAVERSE Trial in RCC
ALLO-316 is the only allogeneic CAR T therapy to show potential in solid tumors. Enrollment has completed in the Phase 1b cohort, which is evaluating the safety and efficacy of ALLO-316 at DL2 (80M CAR T cells) in patients with heavily pretreated advanced or metastatic RCC. The Company will present updated data from the Phase 1b cohort in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2025, in Chicago, Illinois.
2025 First Quarter Financial Results
- Research and development expenses were
$50.2 million for the first quarter of 2025, which includes$5.0 million of non-cash stock-based compensation expense. - General and administrative expenses were
$15.0 million for the first quarter of 2025, which includes$7.1 million of non-cash stock-based compensation expense. - Net loss for the first quarter of 2025 was
$59.7 million , or$0.28 per share, including non-cash stock-based compensation expense of$12.2 million . - The Company had
$335.5 million in cash, cash equivalents, and investments as of March 31, 2025.
In recognition of the evolving macroeconomic environment and the importance of preserving capital, the Company has taken steps to optimize its operations and extend the financial runway. Strategic cost-realignment efforts have been implemented to prioritize high-impact, value-generating programs, which include the clinical advancement of cema-cel in the ALPHA3 trial and ALLO-329 in the RESOLUTION trial. Operational savings have been achieved through a tactical reduction in manufacturing operations, leveraging prior infrastructure investments and the inherent efficiencies of the Company’s allogeneic CAR T platform, while preserving core capabilities. These actions have extended the cash runway into the second half of 2027, allowing the Company to strengthen its ability to weather market uncertainty as it executes clinical programs through key milestones. As a result of these efforts, new guidance for 2025 is an expected decrease in cash, cash equivalents, and investments of approximately
Conference Call and Webcast Details
Allogene will host a live conference call and webcast today at 2:00 p.m. PT / 5:00 p.m. ET to discuss financial results and provide a business update. If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call, which will identify you as the participant and allow you the option to ask a question. The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “expected,” “awaiting,” “projected,” “potential,” “targeted,” “believes,” “will,” “aims to,” “scheduled to,” “drive,” “guidance,” “estimated,” “advancing,” “may,” “could,” “designed to,” “defining,” “can,” “accelerate,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: ALPHA3 being a pivotal trial and the extent to which it will support regulatory approval of cema-cel; that ALPHA3 could transform the role of CAR T in first line LBCL; the potential for an investigational MRD test to identify high-risk patients and for cema-cel as a 1L consolidation therapy for LBCL; the potential that early intervention with cema-cel can improve event-free survival compared to standard of care observation; the ability to expand the ALPHA3 trial footprint outside of the U.S.; that expanding the trial footprint outside the U.S., refining patient identification strategies, earlier patient engagement, educating patients on their relapse risk, and/or strengthening partnerships with sites will lead to greater success in identifying patients, accelerating enrollment, and strengthening trial execution on the ALPHA3 trial; that ALLO-329 offers a novel approach and can break new ground in treating autoimmune disease; the ability for a dual-targeted CD19/CD70 allogeneic CAR T to safely and effectively treat a range of autoimmune indications; the ability for our Dagger technology in ALLO-329 to reduce or eliminate the need for lymphodepletion and induce broader adoption of CAR T therapies in autoimmune indications; the potential for ALLO-329 and the RESOLUTION trial to treat patients with systemic lupus erythematosus, including lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis; the potential for ALLO-316 to safely and effectively treat patients with advanced or metastatic RCC; the ability for CD70 Dagger technology to drive robust CAR T cell expansion and persistence; that the data and results from our Phase 1B TRAVERSE trial can be validated in future trials; the potential for our product candidates to safely treat cancer or autoimmune diseases, including as an “off-the-shelf” product; the pace, timing and extent to which we may initiate or enroll patients in our clinical trials or release data from such trials including ALPHA3, RESOLUTION, and TRAVERSE trials; our projected financial position, our expectation that our cash runway extends into the second half of 2027; financial guidance for 2025; and other statements related to future events or conditions. Various factors may cause material differences between Allogene’s expectations and actual results, including, risks and uncertainties related to: our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval; the limited nature of our pre-clinical and Phase 1 data and the extent to which such data may or may not be validated in any future clinical trial; our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval or limit their commercial potential; the extent to which the Food and Drug Administration disagrees with our clinical or regulatory plans or the import of our clinical results, which could cause future delays to our clinical trials, including initiation of clinical trials, or require additional clinical trials; we may encounter difficulties enrolling patients in our clinical trials; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization; and the challenges with manufacturing or optimizing manufacturing of our product candidates. These and other risks are discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation under the “Risk Factors” heading in its Annual Report on Form 10-Q for the quarter ended March 31, 2025, being filed with the SEC today. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ and Dagger® are trademarks of Allogene Therapeutics, Inc.
CLARITY™ and PhasED-Seq™ are trademarks of Foresight Diagnostics.
Allogene’s investigational AlloCAR T™ oncology products utilize Cellectis technologies. The anti-CD19 oncology products are developed based on an exclusive license granted by Cellectis to Servier. Servier, which has an exclusive license to the anti-CD19 AlloCAR T investigational products from Cellectis, has granted Allogene exclusive rights to these products in the U.S., all EU Member States and the United Kingdom. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T program. ALLO-329 (CD19/CD70) in autoimmune disease uses CRISPR gene-editing technology.
ALLOGENE THERAPEUTICS, INC.
SELECTED FINANCIAL DATA
(unaudited; in thousands, except share and per share data)
| STATEMENTS OF OPERATIONS | |||||||
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Collaboration revenue - related party | $ | — | $ | 22 | |||
| Operating expenses: | |||||||
| Research and development | $ | 50,200 | $ | 52,259 | |||
| General and administrative | 14,991 | 17,267 | |||||
| Total operating expenses | 65,191 | 69,526 | |||||
| Loss from operations | (65,191 | ) | (69,504 | ) | |||
| Other income (expense), net: | |||||||
| Interest and other income, net | 5,516 | 5,433 | |||||
| Interest expense | (150 | ) | — | ||||
| Other income (expenses), net | 92 | (929 | ) | ||||
| Total other income (expense), net | 5,458 | 4,504 | |||||
| Net loss | $ | (59,733 | ) | $ | (65,000 | ) | |
| Net loss per share, basic and diluted | $ | (0.28 | ) | $ | (0.38 | ) | |
| Weighted-average number of shares used in computing net loss per share, basic and diluted | 215,358,619 | 169,128,362 | |||||
| SELECTED BALANCE SHEET DATA | |||||||
| As of March 31, 2025 | As of December 31, 2024 | ||||||
| Cash, cash equivalents and investments | $ | 335,549 | $ | 373,149 | |||
| Total assets | 507,982 | 548,710 | |||||
| Total liabilities | 122,589 | 126,531 | |||||
| Total stockholders’ equity | 385,393 | 422,179 | |||||
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ
What were Allogene Therapeutics (ALLO) key financial results for Q1 2025?
Why was the ALPHA3 trial lymphodepletion analysis delayed for ALLO?
How many sites are activated for Allogene's ALPHA3 trial?
What is Allogene's (ALLO) cash runway projection after recent cost realignment?
What are the key clinical trials in Allogene's pipeline for 2025?
